REFERENCES
Alshamy Z, Richardson KC, Hünigen H, Hafez HM, Plendl J, & Al Masri S
(2018). Comparison of the gastrointestinal tract of a dual-purpose to a
broiler chicken line: A qualitative and quantitative macroscopic and
microscopic study. PLoS ONE.
Anderson CMH, & Thwaites DT (2005). Indirect regulation of the
intestinal H+-coupled amino acid transporter hPAT1 (SLC36A1). Journal of
Cellular Physiology.
Barone S, Fussell SL, Singh AK, Lucas F, Xu J, Kim C, et al.(2009). Slc2a5 (Glut5) is essential for the absorption of fructose in
the intestine and generation of fructose-induced hypertension. Journal
of Biological Chemistry.
Beaufils F, Mas E, Mittaine M, Addra M, Fayon M, Delhaes L, et
al. (2020). Increased fecal calprotectin is associated with worse
gastrointestinal symptoms and quality of life scores in children with
cystic fibrosis. Journal of Clinical Medicine.
Bleich A, & Tolba RH (2017). How can we assess their suffering? German
research consortium aims at defining a severity assessment framework for
laboratory animals.
Block GA, Bleyer AJ, Silva AL, Weiner DE, Lynn RI, Yang Y, et al.(2021). Safety and Efficacy of Tenapanor for Long-term Serum Phosphate
Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial
(PHREEDOM). Kidney360.
Borowitz D, & Gelfond D (2013). Intestinal complications of cystic
fibrosis.
Bradford EM, Sartor MA, Gawenis LR, Clarke LL, & Shull GE (2009).
Reduced NHE3-mediated Na+ absorption increases survival and decreases
the incidence of intestinal obstructions in cystic fibrosis mice.
American Journal of Physiology - Gastrointestinal and Liver Physiology.
Bruzzese E, Raia V, Gaudiello G, Polito G, Buccigrossi V, Formicola
V, et al. (2004). Intestinal inflammation is a frequent feature
of cystic fibrosis and is reduced by probiotic administration.
Alimentary Pharmacology and Therapeutics.
Carroll W, Green J, & Gilchrist FJ (2021). Interventions for preventing
distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.
Clarke LL, Gawenis LR, Franklin CL, & Harline MC (1996). Increased
Survival of CFTR Knockout Mice with an Oral Osmotic Laxative. Laboratory
Animal Science.
Crites KSM, Morin G, Orlando V, Patey N, Cantin C, Martel J, et
al. (2015). CFTR Knockdown induces proinflammatory changes in
intestinal epithelial cells. Journal of Inflammation (United Kingdom).
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz
MA, et al. (2018). Experimental design and analysis and their
reporting II: updated and simplified guidance for authors and peer
reviewers.
De Lisle RC (2007). Altered transit and bacterial overgrowth in the
cystic fibrosis mouse small intestine. American Journal of Physiology -
Gastrointestinal and Liver Physiology.
Dellschaft NS, Ng C, Hoad C, Marciani L, Spiller R, Stewart I, et
al. (2021). Magnetic resonance imaging of the gastrointestinal tract
shows reduced small bowel motility and altered chyme in cystic fibrosis
compared to controls. Journal of Cystic Fibrosis.
Dorsey J, & Gonska T (2017). Bacterial overgrowth, dysbiosis,
inflammation, and dysmotility in the Cystic Fibrosis intestine. Journal
of Cystic Fibrosis.
Faul F, Erdfelder E, Lang AG, & Buchner A G*Power 3: A flexible
statistical power analysis program for the social, behavioral, and
biomedical sciences.
Foulke-Abel J, In J, Yin J, Zachos NC, Kovbasnjuk O, Estes MK, et
al. (2016). Human Enteroids as a Model of Upper Small Intestinal Ion
Transport Physiology and Pathophysiology. Gastroenterology.
Gallagher AM, & Gottlieb RA (2001). Proliferation, not apoptosis,
alters epithelial cell migration in small intestine of CFTR null mice.
American Journal of Physiology - Gastrointestinal and Liver Physiology.
Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli
F, et al. (2012). Oxidative stress and antioxidant therapy in
cystic fibrosis.
Gilchrist FJ, Green J, & Carroll W (2021). Interventions for treating
distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.
Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach
A, et al. (2022). Effects of Elexacaftor/Tezacaftor/Ivacaftor
Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
F508del Alleles. American Journal of Respiratory and Critical Care
Medicine.
Hayee BH, Watson KL, Campbell S, Simpson A, Farrell E, Hutchings
P, et al. (2019). A high prevalence of chronic gastrointestinal
symptoms in adults with cystic fibrosis is detected using tools already
validated in other GI disorders. United European Gastroenterology
Journal.
Hite M, Gaertner WB, Garcia B, Flume P, Maxwell JP, George VV, et
al. (2022). Abdominal Surgical Procedures in Adult Patients with Cystic
Fibrosis. Diseases of the Colon & Rectum.
Honda S, Loher P, Morichika K, Shigematsu M, Kawamura T, Kirino Y,
et al. (2017). Increasing cell density globally enhances the biogenesis
of Piwi-interacting RNAs in Bombyx mori germ cells. Scientific Reports.
Houwen RH, Van Der Doef HP, Sermet I, Munck A, Hauser B, Walkowiak
J, et al. (2010). Defining DIOS and constipation in cystic
fibrosis with a multicentre study on the incidence, characteristics, and
treatment of DIOS. Journal of Pediatric Gastroenterology and Nutrition.
Jakab RL, Collaco AM, & Ameen NA (2011). Physiological relevance of
cell-specific distribution patterns of CFTR, NKCC1, NBCe1, and NHE3
along the crypt-villus axis in the intestine. American Journal of
Physiology - Gastrointestinal and Liver Physiology.
Jaudszus A, Pfeifer E, Lorenz M, Beiersdorf N, Hipler UC, Zagoya
C, et al. (2022). Abdominal Symptoms Assessed with the
CFAbd-Score are Associated with Intestinal Inflammation in Patients with
Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition.
Johansson S, Rosenbaum DP, Palm J, Stefansson B, Knutsson M, Lisbon
EA, et al. (2017). Tenapanor administration and the activity of
the H+-coupled transporter PepT1 in healthy volunteers. British Journal
of Clinical Pharmacology.
Kini A, Singh AK, Riederer B, Yang I, Tan Q, di Stefano G, et al.(2020). Slc26a3 deletion alters pH-microclimate, mucin biosynthesis,
microbiome composition and increases the TNFα expression in murine
colon. Acta Physiologica.
Kini A, Zhao B, Basic M, Roy U, Iljazovic A, Odak I, et al.(2022). Upregulation of antimicrobial peptide expression in slc26a3-/-
mice with colonic dysbiosis and barrier defect. Gut Microbes.
Lavie M, Manovitz T, Vilozni D, Levy-Mendelovich S, Sarouk I, Weintraubv
I, et al. (2015). Long-term follow-up of distal intestinal
obstruction syndrome in cystic fibrosis. World Journal of
Gastroenterology.
Lisowska A, Mdry E, Pogorzelski A, Szydłowski J, Radzikowski A, &
Walkowiak J (2010). Small intestine bacterial overgrowth does not
correspond to intestinal inflammation in cystic fibrosis. Scandinavian
Journal of Clinical and Laboratory Investigation.
Liu J, Walker NM, Cook MT, Ootani A, & Clarke LL (2012). Functional
Cftr in crypt epithelium of organotypic enteroid cultures from murine
small intestine. American Journal of Physiology - Cell Physiology.
Lord R, Fairbourn N, Mylavarapu C, Dbeis A, Bowman T, Chandrashekar
A, et al. (2018). Consuming genistein improves survival rates in
the absence of laxative in ∆F508-CF female mice. Nutrients.
Malagelada C, Bendezú RA, Seguí S, Vitrià J, Merino X, Nieto A, et
al. (2020). Motor dysfunction of the gut in cystic fibrosis.
Neurogastroenterology and Motility.
Malmberg EK, Noaksson KA, Phillipson M, Johansson MEV,
Hinojosa-Kurtzberg M, Holm L, et al. (2006). Increased levels of
mucins in the cystic fibrosis mouse small intestine, and modulator
effects of the Muc1 mucin expression. American Journal of
Physiology-Gastrointestinal and Liver Physiology 291:G203-G210.
Munck A, Alberti C, Colombo C, Kashirskaya N, Ellemunter H, Fotoulaki
M, et al. (2016). International prospective study of distal
intestinal obstruction syndrome in cystic fibrosis: Associated factors
and outcome. Journal of Cystic Fibrosis.
Norkina O, Kaur S, Ziemer D, & De Lisle RC (2004). Inflammation of the
cystic fibrosis mouse small intestine. American Journal of Physiology -
Gastrointestinal and Liver Physiology.
Ooi CY, Syed SA, Rossi L, Garg M, Needham B, Avolio J, et al.(2018). Impact of CFTR modulation with Ivacaftor on Gut Microbiota and
Intestinal Inflammation. Scientific Reports.
Parmley RR, & Gendler SJ (1998). Cystic fibrosis mice lacking Muc1 have
reduced amounts of intestinal mucus. Journal of Clinical Investigation.
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M,
et al. (2020). The ARRIVE guidelines 2.0: Updated guidelines for
reporting animal research. British Journal of Pharmacology.
Philp AR, Riquelme TT, Millar-Büchner P, González R, Sepúlveda FV, Cid
LP, et al. (2018). Kcnn4 is a modifier gene of intestinal cystic
fibrosis preventing lethality in the CFTR-F508del mouse. Scientific
Reports.
Raia V, Maiuri L, De Ritis G, De Vizia B, Vacca L, Conte R, et
al. (2000). Evidence of chronic inflammation in morphologically normal
small intestine of cystic fibrosis patients. Pediatric Research.
Ratcliff R, Evans MJ, Cuthbert AW, MacVinish LJ, Foster D, Anderson
JR, et al. (1993). Production of a severe cystic fibrosis
mutation in mice by gene targeting. Nature Genetics 4: 35-41.
Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, Taft
PJ, et al. (2008). Disruption of the CFTR gene produces a model
of cystic fibrosis in newborn pigs. Science.
Sharma A, Morton A, Peckham D, & Jayne D (2012). Gastrointestinal
surgery in adult patients with cystic fibrosis. Frontline
Gastroenterology.
Shawki A, Engevik MA, Kim RS, Knight PB, Baik RA, Anthony SR, et
al. (2016). Intestinal brush-border Na+/H+ exchanger-3 drives
H+-coupled iron absorption in the mouse. American Journal of Physiology
- Gastrointestinal and Liver Physiology.
Simpson JE, Gawenis LR, Walker NM, Boyle KT, & Clarke LL (2005).
Chloride conductance of CFTR facilitates basal Cl -/HCO 3- exchange in
the villous epithelium of intact murine duodenum. American Journal of
Physiology - Gastrointestinal and Liver Physiology.
Sinagra E, Rossi F, Raimondo D, Conoscenti G, Anderloni A, Guarnotta
V, et al. (2020). Tenapanor for the treatment of irritable bowel
syndrome with constipation. Expert Review of Clinical Pharmacology.
Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies
O, et al. (1992). An animal model for cystic fibrosis made by
gene targeting. Science.
Stoltz DA, Rokhlina T, Ernst SE, Pezzulo AA, Ostedgaard LS, Karp
PH, et al. (2013). Intestinal CFTR expression alleviates meconium
ileus in cystic fibrosis pigs. Journal of Clinical Investigation.
Strubberg AM, Liu J, Walker NM, Stefanski CD, MacLeod RJ, Magness
ST, et al. (2018). Cftr Modulates Wnt/β-Catenin Signaling and
Stem Cell Proliferation in Murine Intestine. Cellular and Molecular
Gastroenterology and Hepatology 5: 253-271.
Talebi S, Day AS, Rezaiyan MK, Ranjbar G, Zarei M, Safarian M, et
al. (2022). Fecal Calprotectin and Phenotype Severity in Patients with
Cystic Fibrosis: A Systematic Review and Meta-Analysis. Pediatric
Gastroenterology, Hepatology and Nutrition.
Tan Q, di Stefano G, Tan X, Renjie X, Römermann D, Talbot SR, et
al. (2021). Inhibition of Na+/H+ exchanger isoform 3 improves gut
fluidity and alkalinity in cystic fibrosis transmembrane conductance
regulator-deficient and F508del mutant mice. British Journal of
Pharmacology.
Tétard C, Mittaine M, Bui S, Beaufils F, Maumus P, Fayon M, et
al. (2020). Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor
in Adolescents With Cystic Fibrosis. Journal of pediatric
gastroenterology and nutrition.
Thwaites DT, & Anderson CMH (2007). H+-coupled nutrient, micronutrient
and drug transporters in the mammalian small intestine.
Vitko M, Valerio DM, Rye PD, Onsøyen E, Myrset AH, Dessen A, et
al. (2016). A novel guluronate oligomer improves intestinal transit and
survival in cystic fibrosis mice. Journal of Cystic Fibrosis.
Walker NM, Simpson JE, Levitt RC, Boyle KT, & Clarke LL (2006).
Talniflumate increases survival in a cystic fibrosis mouse model of
distal intestinal obstructive syndrome. Journal of Pharmacology and
Experimental Therapeutics.
Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman
J, et al. (2010). Evidence of intestinal inflammation in patients
with cystic fibrosis. Journal of Pediatric Gastroenterology and
Nutrition.
Xiao F, Li J, Singh AK, Riederer B, Wang J, Sultan A, et al.(2012). Rescue of epithelial HCO 3 − secretion in murine intestine by
apical membrane expression of the cystic fibrosis transmembrane
conductance regulator mutant F508del. The Journal of Physiology
590: 5317-5334.